scispace - formally typeset
D

Dina Radenkovic

Researcher at King's College London

Publications -  6
Citations -  356

Dina Radenkovic is an academic researcher from King's College London. The author has contributed to research in topics: Cholesterol & Interstitial cell of Cajal. The author has an hindex of 4, co-authored 6 publications receiving 104 citations. Previous affiliations of Dina Radenkovic include St Thomas' Hospital.

Papers
More filters
Journal ArticleDOI

SARS-CoV-2, COVID-19 and the Ageing Immune System.

TL;DR: In this article, the authors discuss the ageing immune system and its ability to respond to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and propose interventions aimed at immunosenescence could enhance immune function not only in the elderly but in susceptible younger individuals, ultimately improving complications of severe COVID-19 for all ages.
Journal ArticleDOI

Cholesterol in relation to covid‐19: Should we care about it?

TL;DR: The role of cholesterol level in the process of the coronavirus infection is elaborated and a critical appraisal on the potential of statins in reducing the severity, duration, and complications of COVID-19 is provided.
Journal ArticleDOI

The Effect of Low-Fat and Low-Carbohydrate Diets on Weight Loss and Lipid Levels: A Systematic Review and Meta-Analysis

TL;DR: This meta-analysis suggests that low-carbohydrate diets are effective at improving weight loss, HDL and TG lipid profiles, however, this must be balanced with potential consequences of raised LDL and total cholesterol in the long-term.
Journal ArticleDOI

Pathophysiology of Cardiovascular Complications in COVID-19

TL;DR: There is a need to establish clear clinical and follow-up protocols and to identify and treat possible comorbidities that may be risk factors for the development of cardiovascular complications.
Journal ArticleDOI

Panomics: New Databases for Advancing Cardiology

TL;DR: This paper identified 104 omic databases, of which 72 met the inclusion criteria: genomic and clinical measurements on a subset of the database population plus one or more omic datasets, 65 were methylomic, 59 transcriptomic, 41 proteomic, 42 metabolomic, and 22 microbiomic databases.